Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

27

Revenue 2017

Gilenya

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Gilenya was produced by Novartis.

CHMP recommends eight new medicines for EU approval

CHMP recommends eight new medicines for EU approval

a generic of Novartis’ Gilenya, for relapsing-remitting multiple sclerosis with high disease activity.

J&J’s MS drug ponesimod receives approval in the US

J&J’s MS drug ponesimod receives approval in the US Now that Ponvory has received regulatory approval, it will enter an increasingly crowded market, with rivals including Novartis’ SLP receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod). ... There is also

Cortellis Drugs to Watch in 2020 report

Cortellis Drugs to Watch in 2020 report To succeed, it will have to differentiate from its direct competitors, particularly the first-in-class S1P1 agonist Gilenya, by leveraging potential cardiovascular safety advantages.

J&J aims for US approval of MS drug ponesimod

J&J aims for US approval of MS drug ponesimod If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only ... There is also the

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

J&J’s ponesimiod tops Aubagio in head-to-head MS trial S1P receptor modulator franchise based on Gilenya(fingolimod) and recently-launched follow-up  Mayzent(siponimod), which for now is approved for secondary progressive forms of MS only. ... There is also a looming threat of generic competition to Gilenya

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...